

Daniela Verthelyi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5005270/publications.pdf>

Version: 2024-02-01

68
papers

5,099
citations

117625

34
h-index

102487

66
g-index

73
all docs

73
docs citations

73
times ranked

5965
citing authors

#	ARTICLE	IF	CITATIONS
1	NK cells require immune checkpoint receptor LILRB4/gp49B to control neurotropic Zika virus infections in mice. JCI Insight, 2022, 7, .	5.0	5
2	2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CART-Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (Part 3) Recommendations on Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7	1.5	31
3	2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback (Part 2) Recommendations on Tj ETQq1 1 0.784314 rgBT /Overlock	1.5	16
4	Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSV ^G -EBOV-GP infection model. Emerging Microbes and Infections, 2021, 10, 2076-2089.	6.5	3
5	An In Vitro Assessment of Immunostimulatory Responses to Ten Model Innate Immune Response Modulating Impurities (IIRMI)s and Peptide Drug Product, Teriparatide. Molecules, 2021, 26, 7461.	3.8	7
6	The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. Nature Immunology, 2020, 21, 1146-1151.	14.5	82
7	CpG Oligonucleotides Protect Mice From Alphavirus Encephalitis: Role of NK Cells, Interferons, and TNF. Frontiers in Immunology, 2020, 11, 237.	4.8	8
8	CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis. PLoS Neglected Tropical Diseases, 2020, 14, e0008050.	3.0	17
9	Long-term persistence of infectious Zika virus: Inflammation and behavioral sequela in mice. PLoS Pathogens, 2020, 16, e1008689.	4.7	29
10	Title is missing!. , 2020, 14, e0008050.		0
11	Title is missing!. , 2020, 14, e0008050.		0
12	Title is missing!. , 2020, 14, e0008050.		0
13	Immunogenicity Risks for Naturally Derived Complex Drugs. AAPS Advances in the Pharmaceutical Sciences Series, 2019, , 219-244.	0.6	0
14	Pseudovirus rVSV ^G -ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice. Cell Reports, 2019, 26, 1718-1726.e4.	6.4	29
15	2019 White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs (Part 2) Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV Tj ETQq1 1 0.784314 rgBT /Overlock 18	1.5	18
16	IL-6 Impairs Vaccine Responses in Neonatal Mice. Frontiers in Immunology, 2018, 9, 3049.	4.8	19
17	2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2) PK, PD & ADA assays by hybrid LBA/LCMS & regulatory Tj ETQq1 1 0.784314 rgBT /Overlock	1.5	18
18	2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (Part 3) LBA/cell-based assays: immunogenicity, biomarkers and PK Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		

#	ARTICLE	IF	CITATIONS
19	ZIKA virus infection causes persistent chorioretinal lesions. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-15.	6.5	45
20	Aggregates of IVIG or Avastin, but not HSA, modify the response to model innate immune response modulating impurities. <i>Scientific Reports</i> , 2018, 8, 11477.	3.3	25
21	In Vivo Effect of Innate Immune Response Modulating Impurities on the Skin Milieu Using a Macaque Model: Impact on Product Immunogenicity. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 751-760.	3.3	19
22	PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses. <i>Thrombosis Research</i> , 2017, 159, 39-47.	1.7	14
23	Cell based assay identifies TLR2 and TLR4 stimulating impurities in Interferon beta. <i>Scientific Reports</i> , 2017, 7, 10490.	3.3	20
24	CD4 and CD8 T cells mediate distinct lethal meningoencephalitis in mice challenged with Tacaribe arenavirus. <i>Cellular and Molecular Immunology</i> , 2017, 14, 90-107.	10.5	19
25	Regulation of the maturation of human monocytes into immunosuppressive macrophages. <i>Blood Advances</i> , 2017, 1, 2510-2519.	5.2	29
26	Zika (PRVABC59) Infection Is Associated with T cell Infiltration and Neurodegeneration in CNS of Immunocompetent Neonatal C57Bl/6 Mice. <i>PLoS Pathogens</i> , 2016, 12, e1006004.	4.7	146
27	Detection of Innate Immune Response Modulating Impurities in Therapeutic Proteins. <i>PLoS ONE</i> , 2015, 10, e0125078.	2.5	55
28	Glycosylation, Hypogammaglobulinemia, and Resistance to Viral Infections. <i>New England Journal of Medicine</i> , 2014, 370, 1615-1625.	27.0	117
29	Scientific considerations in the review and approval of generic enoxaparin in the United States. <i>Nature Biotechnology</i> , 2013, 31, 220-226.	17.5	67
30	Assessment of the cellular internalization of thermolytic phosphorothioate DNA oligonucleotide prodrugs. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 6224-6232.	3.0	11
31	High-Throughput Quantitative Real-Time Polymerase Chain Reaction Array for Absolute and Relative Quantification of Rhesus Macaque Types I, II, and III Interferon and Their Subtypes. <i>Journal of Interferon and Cytokine Research</i> , 2012, 32, 407-415.	1.2	7
32	Expression profiles of human interferon- α and interferon- λ subtypes are ligand- and cell-dependent. <i>Immunology and Cell Biology</i> , 2012, 90, 774-783.	2.3	97
33	Regulatory T Cells in γ Irradiation-Induced Immune Suppression. <i>PLoS ONE</i> , 2012, 7, e39092.	2.5	29
34	Managing uncertainty: A perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 3560-3567.	3.3	91
35	Mucosal and Peripheral Lin ⁺ HLA-DR ⁺ CD11c/123 ⁺ CD13 ⁺ CD14 ⁺ Mononuclear Cells Are Preferentially Infected during Acute Simian Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2012, 86, 1069-1078.	3.4	24
36	Non-animal replacement methods for human vaccine potency testing: state of the science and future directions. <i>Procedia in Vaccinology</i> , 2011, 5, 16-32.	0.4	23

#	ARTICLE	IF	CITATIONS
37	The acceleration of wound healing in primates by the local administration of immunostimulatory CpG oligonucleotides. <i>Biomaterials</i> , 2011, 32, 4238-4242.	11.4	28
38	TLR9 and TLR7 agonists mediate distinct type I IFN responses in humans and nonhuman primates in vitro and in vivo. <i>Journal of Leukocyte Biology</i> , 2011, 91, 147-158.	3.3	35
39	Expression and regulation in the brain of the chemokine CCL27 gene locus. <i>Journal of Neuroimmunology</i> , 2010, 225, 82-90.	2.3	17
40	Trace Levels of Innate Immune Response Modulating Impurities (IIRMI) Synergize to Break Tolerance to Therapeutic Proteins. <i>PLoS ONE</i> , 2010, 5, e15252.	2.5	53
41	Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 1201-1205.	3.3	492
42	Inhibition of Taq polymerase as a method for screening heparin for oversulfated contaminants. <i>Biomaterials</i> , 2008, 29, 4808-4814.	11.4	39
43	Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. <i>Nature Biotechnology</i> , 2008, 26, 901-908.	17.5	148
44	Immunotherapy with CpG Oligonucleotides and Antibodies to TNF- α Rescues Neonatal Mice from Lethal Arenavirus-Induced Meningoencephalitis. <i>Journal of Immunology</i> , 2008, 180, 8231-8240.	0.8	28
45	GM-CSF Production by Autoreactive T Cells Is Required for the Activation of Microglial Cells and the Onset of Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2007, 178, 39-48.	0.8	338
46	Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. <i>European Journal of Immunology</i> , 2007, 37, 1785-1795.	2.9	101
47	Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates. <i>Nucleic Acids Research</i> , 2006, 34, 6488-6495.	14.5	30
48	Adjuvant Properties of CpG Oligonucleotides in Primates. , 2006, 127, 139-158.		11
49	CpG Oligodeoxynucleotides Protect Newborn Mice from a Lethal Challenge with the Neurotropic Tacaribe Arenavirus. <i>Journal of Immunology</i> , 2006, 176, 4940-4949.	0.8	67
50	Design and Development of Thermolytic DNA Oligonucleotide Prodrugs. <i>Annals of the New York Academy of Sciences</i> , 2005, 1058, 26-38.	3.8	2
51	Prevention and Treatment of Cutaneous Leishmaniasis in Primates by Using Synthetic Type D/A Oligodeoxynucleotides Expressing CpG Motifs. <i>Infection and Immunity</i> , 2005, 73, 4948-4954.	2.2	54
52	Thermolytic CpG-containing DNA oligonucleotides as potential immunotherapeutic prodrugs. <i>Nucleic Acids Research</i> , 2005, 33, 3550-3560.	14.5	30
53	Use of CpG oligodeoxynucleotides as immune adjuvants. <i>Immunological Reviews</i> , 2004, 199, 201-216.	6.0	270
54	CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. <i>Aids</i> , 2004, 18, 1003-1008.	2.2	45

#	ARTICLE	IF	CITATIONS
55	Coinjection with CpG-Containing Immunostimulatory Oligodeoxynucleotides Reduces the Pathogenicity of a Live Vaccine against Cutaneous Leishmaniasis but Maintains Its Potency and Durability. <i>Infection and Immunity</i> , 2003, 71, 5121-5129.	2.2	69
56	CpG Oligodeoxynucleotides Protect Normal and SIV-Infected Macaques from <i>Leishmania</i> Infection. <i>Journal of Immunology</i> , 2003, 170, 4717-4723.	0.8	109
57	Differential signaling by CpG DNA in DCs and B cells: not just TLR9. <i>Trends in Immunology</i> , 2003, 24, 519-522.	6.8	100
58	Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. <i>Clinical Immunology</i> , 2003, 109, 64-71.	3.2	81
59	CpG Oligodeoxynucleotides as Vaccine Adjuvants in Primates. <i>Journal of Immunology</i> , 2002, 168, 1659-1663.	0.8	184
60	CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. <i>European Journal of Immunology</i> , 2002, 32, 2617-2622.	2.9	84
61	Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. <i>Arthritis and Rheumatism</i> , 2002, 46, 2219-2224.	6.7	81
62	CpG DNA: recognition by and activation of monocytes. <i>Microbes and Infection</i> , 2002, 4, 897-901.	1.9	64
63	Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. <i>Journal of Leukocyte Biology</i> , 2002, 71, 813-20.	3.3	127
64	Sex hormones as immunomodulators in health and disease. <i>International Immunopharmacology</i> , 2001, 1, 983-993.	3.8	317
65	Response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides. <i>Veterinary Microbiology</i> , 2001, 78, 353-362.	1.9	102
66	Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs. <i>Journal of Immunology</i> , 2001, 166, 2372-2377.	0.8	493
67	Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety. <i>Seminars in Immunopathology</i> , 2000, 22, 173-184.	4.0	23
68	Immune Recognition of Foreign DNA. <i>Immunity</i> , 1999, 11, 123-129.	14.3	122